Summary:
CiRT
Cardiovascular inflammation reduction trial
CiRT will examine if taking low-dose methotrextate (LDM) once a week will reduce inflammation and decrease the risk for heart attacks, strokes, and death among men and women who have had a heart attack.
You may be eligible to participate in CiRT if you have had a heart attack or have had major blockages in more than one coronary artery in the past and you have been diagnosed with either diabetes or a condition called “metabolic syndrome” which puts you at high risk for developing diabetes.
Qualified Participants May Receive:
Compensation for time and travel.